Ceribell, Inc. ( (CBLL) ) has released its Q3 earnings. Here is a breakdown of the information Ceribell, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ceribell, Inc. is a medical technology company specializing in the development of innovative solutions for diagnosing and managing serious neurological conditions, particularly through its point-of-care EEG platform, the Ceribell System. Based in Sunnyvale, California, the company leverages advanced AI-powered algorithms to enhance patient care in acute settings.
In its third quarter of 2025 financial report, Ceribell, Inc. announced a significant revenue increase, reflecting strong commercial performance and growing adoption of its Ceribell System. The company reported a total revenue of $22.6 million, marking a 31% rise compared to the same period in 2024, alongside a slight improvement in gross margin.
Key financial highlights include a 28% increase in product revenue and a 44% rise in subscription revenue, driven by expansion into new accounts and increased usage among existing customers. Despite these gains, the company reported a net loss of $13.5 million, attributed to higher operating expenses linked to business growth and public company operations.
Looking ahead, Ceribell is optimistic about its market potential, raising its full-year revenue guidance to between $87 million and $89 million, indicating a projected growth of 33% to 36%. The company remains focused on establishing its EEG platform as a standard of care in seizure management, aiming to capitalize on an estimated $2 billion market opportunity.